With a final preclinical study now published, a gene therapy designed by Duke University researchers to improve treatment for the genetic disorder Pompe disease is set to enter a Phase 1 clinical trial. Now, the researchers need to raise the money to fund the trial.

Patients with Pompe disease, which affects infants and can also emerge later in life, lack or have too little of an enzyme called acid alpha-glucosidase, or GAA. GAA helps break down glycogen into fuel for cells, so without GAA, the buildup of glycogen damages muscles and leads to respiratory and heart problems.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • I’m pretty sure I have Pompe disease – late onset. My doctor is submitting the form for the genetic testing. I have tried to learn all I can about this disease. I read about ERT and talked to Genzyme about Lumizyme, and I found that Medicare will cover it but my copay will be $1,000 mo and I will have to take it for the rest of my life – and I’m on low Social Security so that’s not an option. But I wondered if Lumizyme would address the issue of the garbage already stored in the Lysosomes – which it doesn’t. In researching this I found some information about a Gene therapy that addresses this issue and apparently only one treatment is needed. I also read about the participation of the transcription factors TFEB and TFE3 in the regulation of lysosomal function and biogenesis and there were references to treatment with something called Trehalose. I would like to learn more about these treatments and I sure would like to be part of your clinical trials or do whatever it takes to get these treatments!

  • I am 63 years old and my onset for pompe was about 7 years ago. Please inform me of any new developments on this research. Thank you. 5-1-17

  • You can call it a “ferry virus”, but viral vectors in gene therapy have proven to be anything but innocuous, especially adenoviral vectors. Study the case of Jesse Gelsinger, who received gene therapy for ornithine decarboxylase deficiency, which killed him post haste. He would still be alive today if he were simply given a protein sparing diet.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy